10 results about "Gastrointestinal inflammation" patented technology

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The invention belongs to the technical field of special medical food, and relates to application of common turnip in products for inhibiting gastrointestinal tract helicobacter pylori. The common turnip extract has the function of treating or preventing helicobacter pylori infection, has a good improvement effect on prevention and inhibition of gastroenteritis caused by helicobacter pylori, remarkably improves the function of a digestive system, and can be used for preventing and treating the gastroenteritis caused by the helicobacter pylori and preventing and treating the gastroenteritis caused by the helicobacter pylori. And support is provided for developing novel dietary nutrition supplements, functional foods, special medical foods and pharmaceutical compositions for inhibiting helicobacter pylori. The invention further discloses a synergistic effect of a medicinal and edible composition formed by combining the common turnip extract with extracts of clove, codonopsis pilosula, hericium erinaceus, fructus amomi and the like on inhibition of helicobacter pylori, and a greater effect of inhibiting the activity of the helicobacter pylori can be achieved. The novel product for inhibiting helicobacter pylori developed by the invention has both safety and effectiveness, and has a very good application prospect.

A composition for young children comprising glycosphingolipids. The present invention relates to a composition comprising one or more glycosphingolipids, to a nutritional formula for children comprising said composition, to the use of said composition for supporting healthy growth and development of young children, in particular infants, and for dietary management of symptoms related to inflammation of the gastrointestinal tract system of said young children. In particular, the present invention relates to a composition comprising one or more compounds of formula (1) or salts thereof: wherein R1 is a C13-C17 alkyl chain; r2 is a C15-C19 alkyl chain; and R3 is a glycosyl moiety selected from Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-or Neu5Ac [alpha] 2-8-Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-. Children's nutritional formulas comprising the composition are also provided.

The invention discloses an enterogastritis-related convulsion prediction method and system, and the method comprises the steps: obtaining the historical clinical data of a patient, screening the index data of the occurrence of enterogastritis-related convulsion from the historical clinical data, carrying out the data preprocessing of the collected index data, obtaining multi-modal clinical data, taking the multi-modal clinical data as an input feature, and carrying out the prediction of the enterogastritis-related convulsion. The method comprises the following steps: taking whether a patient has convulsion within a preset time as a prediction target, training to obtain a corresponding convulsion prediction model, inputting clinical data of a to-be-assessed patient into the convulsion prediction model obtained by training to output a convulsion occurrence risk probability value, determining a risk level corresponding to the convulsion occurrence risk probability value, and comprehensively analyzing various factors to determine the risk level of the to-be-assessed patient. The risk of convulsion possibly occurring in the gastroenteritis patient is predicted in advance, so that corresponding prevention measures can be taken in time, the occurrence rate of convulsion is reduced, and the treatment effect and life quality of the patient are improved.

The present invention relates to a composition for use in the prevention or treatment of gastrointestinal infections / inflammation in infants or young children. The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in specific proportions for use in the prevention and / or treatment of gastrointestinal infections and / or gastroenteritis in infants or young children.

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

The present invention provides a composition and method for treating an allergic disease. The composition comprises a ligand for asialoglycoprotein receptor 1 (Asgr1). The allergic disease may be atopic dermatitis, allergic rhinitis, urticaria, allergic asthma, allergic conjunctivitis, allergic gastrointestinal inflammation, or anaphylactic shock. The allergic disease may be caused by house dust mites. The present invention also provides a method for determining if a test compound activates human Asgr1.

The invention discloses a chimonanthus salicifolius extract and a preparation method and application thereof, and belongs to the technical field of medicines.The preparation method comprises the steps that dry chimonanthus salicifolius leaves are subjected to reflux extraction through an ethanol water solution, an ethyl acetate part is obtained through extraction, and then separation and purification are conducted through a silica gel column, gel column chromatography, a reversed-phase C18 column and semi-preparative high performance liquid chromatography in sequence to obtain the chimonanthus salicifolius extract. The high-purity target compound 1 and the high-purity target compound 2 are obtained. Compared with the prior art, an in-vitro cell experiment shows that the compound 1 and the compound 2 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M, the secretion levels of tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-2 (MMP2) can be reduced, the compound 1 can also inhibit the secretion of interleukin-2 (IL-2), and the compound 2 and the compound 1 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M; safe and effective natural medicine candidate molecules are provided for gastrointestinal inflammation diseases such as functional dyspepsia, and the good clinical transformation potential is achieved.